The FDA grants Priority Review status for BeiGene’s (NASDAQ:BGNE) marketing application seeking approval to use BTK inhibitor zanubrutinib to treat patients with mantle cell lymphoma (MCL) who have received at least one prior line of therapy. The agency’s action date is February 27, 2020.
MCL is a rare aggressive form of non-Hodgkin lymphoma (NHL) that originates in the mantle zone of a lymph node.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.